In the case of EBV-associated lymphomas, our results suggest that for BL, which mainly express type I latency, the targeting of IRE1α/XBP1 may be more promising than for post-transplant EBV-positive lymphomas, mainly characterized by type III latency. Here, XBP1 is linked to Burkitt lymphoma.